AstraZeneca Covid-19 shot candidate shows promise among elderly in trials

AstraZeneca COVID-19 vaccine shows promise with the elderly

The European Medicines Agency (EMA) could produce a scientific opinion on COVID-19 vaccines seeking regulatory approval by the end of the year in a best case scenario, the regulator's new chief was quoted as saying on Tuesday. The global battle to secure prospective supplies has raised alarm about equitable access, while questions remain over logistics, distribution, and cost. And there were no serious safety issues relating to the vaccine, called ChAdOx1 nCov-2019.

Furthermore, the team found that the vaccine was less likely to cause local reactions at the injection site and symptoms on the day of vaccination in older adults than in the younger group, demonstrating that assessment of the efficacy of the vaccine is warranted in all age groups. Scientists expect T-cell responses to play a role in long-term immunity against the virus. "These findings are encouraging because older individuals are at disproportionate risk of severe Covid-19 and so any vaccine adopted for use against SARS-CoV-2 [Covid-19] must be effective in older adults", the researchers note.

"We hope that this means our vaccine will help to protect some of the most vulnerable people in society, but further research will be needed before we can be sure".

Three vaccines - Pfizer-BioNTech, Sputnik and Moderna - have already reported good preliminary data from phase three trials, with one suggesting 94 per cent of over-65s could be protected from Covid-19.

Results are expected later this year depending on the rate of infection within clinical trial communities. These included people of all ages.

No adverse health problems were reported during the trials.

The race for the coronavirus vaccine has picked up pace in recent weeks with Pfizer/BioNTech and Moderna announcing the results of phase 3 trials.

BNT162b2 vaccine is 95 percent effective against COVID-19, finds final efficacy analysis...



Latest news

Russia Says Its Sputnik V Coronavirus Vaccine 95% Effective
The statement reported that the effectiveness of Sputnik-V exceeded 95 percent after 42 days of testing. Dr Reddy's will soon start its phase 2 and 3 clinical trial of the vaccine with 1,500 participants.

Australia opens up more borders in domestic travel boost, eyes vaccine
The announcement means people from some areas of Sydney will be allowed into Queensland for the first time since mid-July.

Almost 1600 COVID-19 Cases Confirmed
Of the new cases confirmed today, 460 were reported in Toronto, 490 were in Peel Region, and 130 were in York Region. In the Outaouais, 25 more cases were reported for a sum of 3,240, but the death toll due to COVID-19 remained at 70.

JUST IN: Biden Expected to Pick Janet Yellen as Treasury Secretary
Odds that ex-Fed Chair Yellen will become Treasury Secretary, vaccine hopes and Brexit optimism also favor the bulls. Chief economist at Grant Thornton Diane Swonk called Yellen "a highly talented and gifted economist" on Twitter.

Russias Vladimir Putin not ready to recognise Joe Biden as USA president
Download BRIEFLY's news app on Google Play now and stay up-to-date with major South African news! TASS reported that Putin explained that "Russia's authorities are ready to work with any U.S.

Other news